“Recent studies have demonstrated that up to 20 percent of patients recovering from heart surgery have some form of intervention due to retained blood that can slow recovery and increase the costs of care,” said Edward Boyle, MD, co-founder and chairman of ClearFlow. “The goal of this study is to implement structured protocols in the ICU that can facilitate improved recovery for patients after heart surgery.”
The study will implement the use PlueraFlow ACT, a device created by ClearFlow to prevent chest tubes from clogging in the first 24 to 48 hours after heart surgery.
Paul Molloy, ClearFlow CEO, said, “It’s an honor to work with Mayo Clinic on this research — an organization known worldwide for its commitment to continuous quality improvement to optimize patient care.”
More articles on quality:
CMS to host webinar on overall hospital star ratings methodology
Can EHRs adequately measure care quality for adolescents? 3 study findings
Enhanced communication key to reducing nurse burnout, improving care
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
